A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
UCB received Japanese approval for two self-administration methods for Rystiggo (anti-FcRn) in generalised myasthenia gravis (gMG), allowing patients to use an infusion pump or manual syringe at home after training. To support the label expansion, UCB also launched a home delivery service in Japan to enhance patient convenience and satisfaction. The move aligns with Rystiggo's self-administration approval in the EU earlier this year and could support its positioning amid growing competition. We ...
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.
URW SE - Information on total number of voting rights and shares in the share capital as at April 30, 2025 Paris, May 5th, 2025 Information on total number of voting rights and shares in the share capital as of April 30th, 2025 (Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the AMF) DateTotal number of shares in the capitalTotal number of voting rights30/04/2025143,046,512143,046,512 UNIBAIL-RODAMCO-WESTFIELD SEA European Company with Management Board and Supervisory BoardShare capital: €715,118,210Registered office: 7 place du Chancelier...
URW SE - Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 30 avril 2025 Paris, le 5 mai 2025 Informations relatives au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025 (articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF) DateNombre total d’actions composant le capitalNombre total de droits de vote30/04/2025143 046 512143 046 512 UNIBAIL-RODAMCO-WESTFIELD SESociété Européenne à Directoire et Conseil de surveillanceau capital de 715 118 210 euros Siège social :...
We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.
Convening of the Annual General Meeting to approve the 2024 financial statements to be held on June 13, 2025 and evolution of the Atos Board of Directors Press Release Convening of the Annual General Meeting to approve the 2024 financial statements to be held on June 13, 2025 and evolution of the Atos Board of Directors Paris, France – April 30, 2025 Convening of the 2025 Annual General Meeting The meeting notice (avis de réunion) for the General Meeting scheduled for June 13, 2025, containing the agenda, the draft resolutions, and the participation and voting procedures for this Meetin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.